DISEASE CHARACTERISTICS:

• Histologically confirmed biliary tract cancer (including intrahepatic or extrahepatic/hilar cholangiocarcinoma or muscle invasive gallbladder cancer)

  • Must have undergone a macroscopically complete resection with curative intent that included liver resection

    • No prior resection that involved the pancreas
  • Patients with pathological evidence of microscopic involvement of the margins of the excised specimen are eligible as long as resection is macroscopically complete
• Must be able to start treatment within 8 weeks of surgery
• No pancreatic or periampullary cancer
• No mucosal gallbladder cancer

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2
• Urea < 1.5 times upper limit of normal (ULN)
• Creatinine < 1.5 times ULN
• Glomerular filtration rate ≥ 60 mL/min
• Hemoglobin ≥ 10 g/dL
• WBC ≥ 3,000/mm³
• Absolute neutrophil count ≥ 1,500/mm³
• Platelet count ≥ 100,000/mm³
• Bilirubin < 3 times ULN
• ALT and AST ≤ 5 times ULN
• Adequate surgical biliary drainage with no evidence of infection
• Not pregnant or nursing
• Negative pregnancy test for women of childbearing age and childbearing potential
• Fertile patients must use effective contraception during study treatment and for 3 months after study treatment has ended
• Must provide written informed consent
• No history of other malignant diseases within the past 5 years other than adequately treated nonmelanoma skin cancer or in situ carcinoma of the uterine cervix
• No serious co-existing medical condition, including a potential serious infection that would interfere with study treatment
• No evidence of significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the trial
• No psychological, familial, sociological, or geographical factors considered likely to preclude study compliance
• No other serious uncontrolled medical conditions
• No unresolved biliary tree obstruction

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• Completely recovered from prior surgery
• No use of other investigational agents for 28 days prior to and during study treatment
• No prior chemotherapy or radiotherapy for biliary tract cancer
• No other concurrent anticancer chemotherapy, radiotherapy, or investigational agent